I’ve been digging into the latest spatial proteomics from the Sabatini lab, and honestly, it’s shaking up how I view mTORC1 dynamics. For years, we’ve talked about the mTOR pathway as a diffuse signal—a simple volume knob for protein synthesis—but the data suggests the lysosomal surface might just be one of many theaters of operation, and maybe not even the main one.

What caught me off guard? The translocation kinetics don't match the metabolic shifts we’re seeing. We’re detecting robust kinase activity even when the Rag-GTPase machinery seems partially dissociated. It forces me to consider an uncomfortable possibility: are we missing a significant pool of active mTOR sequestered at the endoplasmic reticulum or the mitochondrial outer membrane? If mTOR’s spatial restriction is more fluid than our amino acid sensing models suggest, then our systemic dosing strategies for rapalogs are likely off. We’re probably hitting the "easy" pools, while the spatially sequestered ones stay insulated.

This makes me worry about the implications for caloric restriction mimetics. If mTOR activity is tethered to specific organelle micro-domains, a global inhibitor might be triggering homeostatic chaos by suppressing signaling in tissues that actually need a localized spike to keep their structure intact.

I’m curious to see what the rest of you think:

• Does the existing literature on LAMTOR complex scaffolding actually account for non-lysosomal localization?
• Are we conflating "activity" with "localization" when we measure S6K phosphorylation?
• Could this spatial heterogeneity explain why human healthspan responses look so erratic compared to the mouse data?

We need to stop treating the cell like a well-stirred beaker. I’m leaning toward the idea that where mTOR is active matters just as much as how much we inhibit it. Thoughts?